Hong Kong Stock Movement: HAIXI PHARMA falls 16.03%, analysts maintain buy rating but struggle to restore market confidence

Hong Kong Stock Movement HAIXI PHARMA fell 16.03%. Based on recent key news: On April 25, HAIXI PHARMA's stock price plummeted, despite analysts maintaining a buy rating. Analysts unanimously set a target price of HKD 298.28, but market dissatisfaction with its current performance led to a drop in stock price to HKD 213.00. On April 25, another analyst also maintained a buy rating for HAIXI PHARMA, setting a target price of HKD 298.28. However, the stock closed at HKD 237.60, reflecting market concerns about its future performance. Recently, analysts generally rated HAIXI PHARMA as moderately buy, with a target price of HKD 298.28, but the stock's poor performance indicates a lack of market confidence. The pharmaceutical industry has been volatile recently, necessitating attention to policy changes. Stocks with High Trading Volume in the Industry CSPC Pharmaceutical Group fell 4.09%. Based on recent news: On April 28, CSPC Pharmaceutical Group announced that its subsidiary CSPC Innovation reported a loss of HKD 93.85 million in the first quarter, a year-on-year increase of 248.88%. The loss was mainly due to the expanded consolidation scope of Giant Biologics, increased R&D investment, and foreign exchange losses, leading to a decline in stock price. On April 27, CSPC Pharmaceutical Group released an announcement stating that CSPC Innovation's first-quarter operating revenue was HKD 666.5 million, a year-on-year increase of 40.82%, but the net loss widened to HKD 93.85 million. The market expressed concerns about its profitability, affecting the stock price. On April 27, CSPC Pharmaceutical Group's SYS6010 (EGFR-ADC) Phase II clinical trial results were disappointing, with an ORR of only 39.2%, raising doubts about commercialization prospects and exacerbating investor concerns about the company's future performance, leading to a decline in stock price. The industry has high concentration, insufficient innovative drugs, and faces transformation pressure. China Biologic Products fell 2.53%. Based on recent key news: On April 27, China Biologic Products announced the repurchase of 1.81 million shares, costing HKD 10.0473 million. This move is generally seen as a sign of the company's confidence in its stock value, but it failed to prevent the stock price from falling. On April 25, Xu Xiao, the first secretary of the Central Committee of the Communist Youth League, led a delegation to inspect China Biologic Products' core unit, Chengdu Tianqing. The company showcased its R&D progress, including AI drug discovery, but such innovations typically viewed as positive failed to boost the stock price. The pharmaceutical industry is accelerating innovation, and market volatility is increasing. WuXi AppTec rose 7.43%. Based on recent key news: On April 28, WuXi AppTec announced its first-quarter performance, with operating revenue increasing by 16.9%, but net profit decreased by 6.8%, mainly due to foreign exchange losses caused by the appreciation of the RMB. This news attracted market attention, driving the stock price up. On April 27, Goldman Sachs released a report maintaining a "buy" rating on WuXi AppTec, believing that its CDMO business cycle is robust, and the visibility of commercialization projects has improved, enhancing investor confidence, which led to an increase in stock price On April 27th, Zhitong Finance reported that Kelaiying's first-quarter performance showed an improvement in gross margin for emerging businesses, an increase in delivery scale and capacity utilization, and the market is optimistic about its future growth expectations, benefiting the stock price. The pharmaceutical industry cycle is stable, with significant capital inflow. Stocks ranked among the top in industry market capitalization Hengrui Medicine fell by 0.67%. Based on recent key news: On April 27th, Hengrui Medicine collaborated with Kailera to advance the GLP-1 product portfolio, expecting to enjoy global value-added benefits from innovative assets in the next 3-5 years. This collaboration enhances the certainty of the company's international development, but recent fluctuations in the Hong Kong stock market's pharmaceutical sector have affected the stock price. On April 27th, a report from CMB International pointed out that Hengrui Medicine's first-quarter performance continued to show high growth, with innovative drug sales revenue increasing by 26% year-on-year, and non-oncology products performing well. The report raised the company's profit margin forecast, setting a target price of HKD 74, maintaining a neutral rating. On April 25th, although the increase in indirect financing scale led to a slight rise in the proportion of interest-bearing liabilities, Hengrui Medicine's financial leverage is generally controllable, with high asset quality that can support the company's sustainable development. The Hong Kong stock market's pharmaceutical sector has recently experienced fluctuations, with weak liquidity